1. XIENCE V vs TAXUS: Game Over! The Studies are Definitive
Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular Santa Clara, CA
CRT 2010

2. Charles A. Simonton, MD DISCLOSURES
Chief Medical Officer Abbott Vascular Santa Clara, CA

3. It’s All About Level of Evidence = A
The data now available for the direct comparison of clinical outcomes comparing Xience V and Taxus is the best we’ve ever had in head-to-head DES clinical trials
WHY?
Prospective, randomized, multicenter trials
Adequately powered for both angiographic and clinical endpoints (SPIRIT II, III, IV and COMPARE)
SPIRIT IV is the largest prospective, randomized, multicenter head-to-head DES trial ever completed that is fully powered for a primary clinical endpoint

4. XIENCE: Best-in-Class Components

5. XIENCE V: Thinnest Struts of Any DES1
CYPHER
TAXUS Liberté
ENDEAVOR
XIENCE V
Strut Thickness:
140 mm
Coating Thickness:
12.6 mm
Strut Thickness:
97 mm
Coating Thickness:
17.8 mm
Strut Thickness:
91 mm
Coating Thickness:
4.8 mm
Strut Thickness:
81 mm
Coating Thickness:
7.8 mm
NEED LIBERTE picture.
Total = um um um um
3.0 mm diameter stents, 500x magnification
1Manufacturer-reported strut thickness. Data on file at Abbott Vascular.

6. XIENCE V: 14-Day Rabbit Iliac Re-endothelialization Study
CYPHER
TAXUS
ENDEAVOR
XIENCE V
Joner et al, JACC 2008
Photos taken by and on file at Abbott Vascular

7. Investment in Clinical Programs: Worldwide DES Clinical Trials
NOTE: For trials that have completed enrollment, numbers are final enrollment. For trials that are planned or still enrolling, numbers are per protocol
XIENCE to be studied in
~29,000
patients
Pre-Approval
Post-Market
Trial Name
# of Enrolling Sites
# of Patients
Time Patients Followed
Trial Name
# of Enrolling Sites
# of Patients
Time Patients Followed
SPIRIT V
SPIRIT Women
XIENCE V USA 2
XIENCE V India
XIENCE V China
XIENCE V Japan
XIENCE V EXCEED
FAR XIENCE V 1
XERES 1
EXECUTIVE 1
102
100
250 19
TBD
110 58 24 30
3,025
2,000
~8,000
1,000
~2,450
~1,900
2,500
1,200
100
600
5 yrs
3 yrs
Acute
2 yrs
SPIRIT FIRST 1
SPIRIT II
SPIRIT III
SPIRIT III Japan
SPIRIT IV
SPIRIT Small Vessel
SPIRIT PRIME 9 28 65 12 58 50 75 60
300
1,002 88
3,690
250
500
5 yrs
1 European Study
2 XIENCE V USA will include a DAPT subset; 5-year patient follow-up on a subset; additional subsets have 33-month or 12-month follow-up
Note: This product is currently CE marked. Where CE marking is not the registration in force, this product may be in Abbott Vascular’s pipeline.
For trials that have completed enrollment, numbers are final enrollment. For trials that are planned or still enrolling, numbers are per protocol 7

8. SPIRIT III Trial Design & Demographics2 : 1
XIENCE V
(N = 669)
TAXUS
(Control = 333)
Up to two de novo lesions, maximum of one lesion per epicardial vessel
RVD: 2.5 – 3.75 mm
LL: 28 mm
N = 1,002
65 US sites
PI: Gregg Stone, MD
RCT: Prospective, single blind
Primary end point: In-segment Late Loss at 8M
Stent Size: 2.5 – 3.5 mm; Stent lengths: 8, 18, 28 mm
Angiographic and IVUS Follow-Up on 564 and 240 pts, respectively
Clinical follow-up at 30, 180, 270d and 1, 2, 3, 4 and 5 years
6 Months clopidogrel for all arms
SPIRIT III Trial Objective
To determine the safety and efficacy of the ML XIENCE V™ EECS System in patients with de novo native coronary artery lesions. SPIRIT III was the pivotal trial in the US for FDA approval.
XIENCE V
TAXUS
P-Value
Patients
669
332 NA
RVD (mm)*
2.77 ±0.5
2.76 ±0.5
Lesion Length (mm)*
14.7 ±5.6
14.7 ±5.7
Diabetics
29.6%
27.9%
0.60% 8
Taxus Express2 was used as the control in SPIRIT III.
*SOURCE: Stone, Gregg, JAMA. Vol 299, No. 16 8

9. SPIRIT III 3-Year Major Adverse Cardiac Events
XIENCE V®
TAXUS®
3-year HR
2-year HR
0.57 [0.39, 0.83]
0.55 [0.37, 0.82]
p=0.003
1-year HR
p=0.003
0.56 [0.35, 0.90]
15.7%
13.1%
p=0.01
MACE (%)
∆6.6%
9.9%
∆5.6%
∆4.2%
9.1%
7.5%
XIENCE V: Delivers long term safety
The difference in MACE between XIENCE V and TAXUS continues to widen between 1, 2 and 3 years with a 43% reduction in MACE at 3 years
5.7%
Number at risk
XIENCE V®
669
652
643
628
612
598
597
591
581
576
574
572
569
TAXUS®
332
312
308
291
286
275
272
269
266
264
260
258
255
Months 9
Taxus Express2 was used as the control in SPIRIT III.
SOURCE: Gregg Stone SPIRIT III 3 Year Results TCT 2009 9

10. Taxus Express2 was used as the control in SPIRIT III.
SPIRIT III 3-Year Landmark Analysis Stent Thrombosis (ARC)
0.3% VLST (ARC Definite + Probable)
0% S.T. between years 2 & 3 in 669 pts
TAXUS
XIENCE V
1-year HR
1.48 [0.30, 7.31]
p=0.63
2-year HR
0.32 [0.05, 1.93]
p=0.19
3-year HR
0.32 [0.05, 1.93]
p=0.19
Stent Thrombosis (%)
0.15% per year = BMS-like
1.0%
1.0%
Low 0.3% very late stent thrombosis rates (ARC Def/Prob) between 1 and 3 years; 0% stent thrombosis rate from 2 to 3 years in 669 patients
XIENCE V had a low 0.3% rate of stent thrombosis between 1 and 3 years, no new ST from years 2 to 3.
0.9%
∆0.7%
∆0.7%
∆-0.6%
0.3%
0.3%
0.3%
Months
Taxus Express2 was used as the control in SPIRIT III.
SOURCE: David Cox SPIRIT III 3 Year Results TCT 2009

11. SPIRIT IV XIENCE V TAXUS Randomized 2:1 XIENCE V:TAXUS Express2
***Clinical f/u only: 1, 6, 9 months and yearly for 1-5 years
***Pt. driven events not impacted by angiographic F/U
***Largest RCT to comparing two DES (↑ diabetic pop.)
100% monitoring: reflects high quality data arising from this trial
RVD ≥2.5 mm - ≤3.75 mm; Lesion length ≤28 mm
Max. 3 lesions with a maximum of 2 per epicardial vessel
Pre-rand: ASA ≥300 mg, clopidogrel ≥300 mg load unless on chronic Rx
3690 pts enrolled at 66 U.S. sites
Randomized 2:1 XIENCE V:TAXUS Express2
Stratified by diabetes and presence of complex lesions
Pre-dilatation mandatory
Everolimus-eluting
XIENCE V
Paclitaxel-eluting
TAXUS
SPIRIT IV Trial Design Key Messages
Largest RCT between two DES to have presented primary endpoint data
One of the largest subsets of patients with diabetes (n=1185 enrolled)
Clinically-driven primary and secondary endpoints – Patient driven events not impacted by angiographic follow-up
100% monitoring – Reflective of the quality of data arising from the trial
Aspirin ≥80 mg QD for 5 years; clopidogrel 75mg QD for at least 12 mos (if not at high risk for bleeding) 11
SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009 11 11

12. Target lesion failure (%)
SPIRIT IV: Primary Endpoint (TLF) Early & Continuously Divergent Differences
HR [95%CI] = [0.46, 0.82]
XIENCE V
TAXUS
p=0.0008
TLF = cardiac death, target vessel MI, and ischemia-driven TLR
6.6%
Number Needed to Treat (NNT) to prevent one TLF Event = 37
Target lesion failure (%)
Δ 2.7%
TAXUS
3.9%
XIENCE V
XIENCE V delivers clinical superiority in the largest RCT between two DES to have presented primary endpoint data.
XIENCE V proved superior to TAXUS in the clinically-driven primary endpoint of target lesion failure (TLF)
(3.9% vs. 6.6%, p=0.0008)
Months
XIENCE V
2458
2390
2362
2323
2298
TAXUS
1229
1165
1137
1119
1104
SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009

13. SPIRIT IV TLF Components
39% ↓ in TLF driven by a 38% ↓ in TV-MI and a 46% ↓ in ID-TLR
XIENCE V
TAXUS
RR [95%CI] =
0.55 [0.38, 0.78]
p=0.001
RR [95%CI] =
0.62 [0.40, 0.96]
p=0.04
46%
Reduction
TLF = cardiac death, target vessel MI, and ischemia-driven TLR
1 Year = 365 ± 28 days
38%
Reduction %
RR [95%CI] =
0.99 [0.34, 2.89]
p=1.00
39% reduction in the risk of TLF driven by reductions in ID-TLR (2.5% vs. 4.6%, p=0.001) and Target Vessel MI (1.8% vs. 2.9%, p=0.04)
10/2416
5/1195
44/2416
35/1195
61/2416
55/1195
Cardiac Death
Target Vessel MI
ID-TLR 13
SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009 13 13

14. NNT (number needed to treat) to avoid 1 ST is only 125 Patients
SPIRIT IV Stent Thrombosis: ARC Definite or Probable
XIENCE V
TAXUS
HR [95%CI] = 0.27 [0.11, 0.67]
p=0.003
NNT (number needed to treat) to avoid 1 ST is only 125 Patients
TAXUS
1.06%
Stent thrombosis (%)
≈73% ↓ in S.T. at 1 year
Δ 0.77%
XIENCE V
XIENCE V delivers long-term safety. 74% reduction in the risk of stent thrombosis (ARC def or prob) at 1 year SPIRIT IV (p=.004).
0.29%
Months
XIENCE V
2458
2426
2412
2388
2376
TAXUS
1229
1195
1184
1174
1166
SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009

15. SPIRIT IV 1-Year Impact of Diabetes on TLF
XIENCE V
TAXUS
RR [95%CI] =
0.47 [0.32, 0.68]
p<0.0001
RR [95%CI] =
0.94 [0.59, 1.49]
p=0.80
TLF (%)
1,140 patients: 6.4% vs. 6.9%
In 1,140 patients with diabetes at 1 year, XIENCE V demonstrated a low 6.4% rate of TLF (vs. 6.9% for TAXUS; p=0.80)
52/1652
55/815
49/761
26/379
Pinteraction = 0.02
TLF = cardiac death, target vessel
MI, or ischemia-driven TLR 15
SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009 15

16. COMPARE Trial XIENCE V vs. TAXUS Liberté
AMI 25 %
Calcification 34 %
Multistenting 62 %
Ostial 19 %
Thrombus 24 %
CTO 4 %
NSTEMI 23 %
Multivessel 27 %
Saphenous graft 2 %
Bifurcation 10 %
Diabetes 18 %
Chronic renal failure 3 %
Left main 2 %
Direct stenting 34 %
“REAL WORLD”
Therefore, we can say that the COMPARE trial truly reflects a real world situation with:……… 16
Smits P, Lancet 2010
SOURCE: Smits COMPARE Trial, TCT 2009 16

17. MACE (All death, non-fatal MI, and TVR)
COMPARE: XIENCE V vs. TAXUS Liberté Primary Endpoint (MACE = Death, MI and TVR)
Taxus
XIENCE
31% ↓ in MACE, p= 0.023
P = (log-rank test)
RR = 0.69 ( )
9.1 %
Δ 2.9 %
Δ 1.1%
6.2 %
XIENCE V is superior to TAXUS Liberté in 1,800 real-world, all comer patients
31% reduction in the primary endpoint of MACE (p=.023)
74% reduction in the secondary endpoint of stent thrombosis (p=0.002)
Benefits of XIENCE V over TAXUS translated across platforms with compelling data in SPIRIT IV and COMPARE (TAXUS is TAXUS!)
This is the result of the primary end-point: the combination of all death, non fatal MI and TVR.
At 12 months follow up, a significant higher incidence of MACE occurred in the Taxus stent group compared to the Xience stent group.
The MACE rate is 9.1% in Taxus versus 6.2% in Xience, which is significant different according the log rank test, with a rate ratio of 0.69 and 95% Confidence Interval of
Of interest is the early difference in events between both groups of 1.1% at 30 days, which gradually increased over time to 2.9% at 12 months follow-up .
# Patients at Risk
MACE (All death, non-fatal MI, and TVR)
Taxus
Xience 17
SOURCE: Smits COMPARE Trial, TCT 2009 17

18. COMPARE: XIENCE V vs. TAXUS Liberté Secondary Endpoint (Stent Thrombosis)
P = (log-rank test)
RR = 0.26 ( )
2.6 %
NNT (number needed to treat) to prevent 1 ST Event is only 53 Patients
74% ↓ in risk of stent thrombosis at 1 year
Definite & probable stent thrombosis rate according to the ARC definitions was also highly significant different between both groups, with a 2.6% in the Taxus group versus 0.7% in the Xience group. This is mainly due to a difference in early stent thrombosis, as shown ……(next dia)
0.7 %
A.R.C. Definite & probable stent thrombosis
SOURCE: Smits COMPARE Trial, TCT 2009 18

19. Xience V versus Taxus Clinical Data: Level of Evidence = A
SPIRIT III – Angiographic superiority over Taxus with efficacy and safety proven long term (3-yrs)
SPIRIT IV – Statistically-significant reduction in TLF and TLR as well as stent thrombosis compared to Taxus, thus showing both improved efficacy and safety, in the largest prospective RCT of DES to date
COMPARE – Outstanding one year safety and efficacy data, again statistically-significant vs. TAXUS Liberte in a real world population 19

20. Xience V versus Taxus
So, Keith, it’s time to put ‘ole Taxus’ out to pasture, as it just can’t keep up with the competition . . .
Taxus

21. And, move on to an exciting new generation of technology!
Xience V versus Taxus
And, move on to an exciting new generation of technology!
Xience V